Close monitoring and early intervention: management principles for cystic fibrosis in Denmark

Tavs Qvist; Bibi Uhre Nielsen; Hanne Vebert Olesen; Inger Hee Mabuza Mathiesen; Daniel Faurholt-Jepsen; Terese L. Katzenstein; Jannik Helweg-Larsen; Frederikke Rönsholt; Majbritt Jeppesen; Mette Frahm Olsen; Frederik Fouirnaies Buchvald; Kim Gjerum Nielsen; Søren Jensen-Fangel; Tania Pressler; Marianne Skov

doi:10.1111/apm.13375

Close monitoring and early intervention: management principles for cystic fibrosis in Denmark

Tavs Qvist^*, Bibi Uhre Nielsen, Hanne Vebert Olesen, Inger Hee Mabuza Mathiesen, Daniel Faurholt-Jepsen, Terese L. Katzenstein, Jannik Helweg-Larsen, Frederikke Rönsholt, Majbritt Jeppesen, Mette Frahm Olsen, Frederik Fouirnaies Buchvald, Kim Gjerum Nielsen, Søren Jensen-Fangel, Tania Pressler, Marianne Skov

^*Corresponding author for this work

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Review › Research › peer-review

4 Citations (Scopus)

Abstract

Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.

Original language	English
Journal	APMIS
Volume	132
Issue	4
Pages (from-to)	223-235
Number of pages	13
ISSN	0903-4641
DOIs	https://doi.org/10.1111/apm.13375
Publication status	Published - Apr 2024

Keywords

benchmarking
clinical practice
guideline
outcome
Standard of care
Anti-Infective Agents/therapeutic use
Cystic Fibrosis/complications
Humans
Europe
Denmark

Access to Document

10.1111/apm.13375

Cite this

Qvist, T., Nielsen, B. U., Olesen, H. V., Mathiesen, I. H. M., Faurholt-Jepsen, D., Katzenstein, T. L., Helweg-Larsen, J., Rönsholt, F., Jeppesen, M., Olsen, M. F., Buchvald, F. F., Nielsen, K. G., Jensen-Fangel, S., Pressler, T., & Skov, M. (2024). Close monitoring and early intervention: management principles for cystic fibrosis in Denmark. APMIS, 132(4), 223-235. https://doi.org/10.1111/apm.13375

@article{cff64b82b5144bc08c1f12b23a402c46,

title = "Close monitoring and early intervention: management principles for cystic fibrosis in Denmark",

abstract = "Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.",

keywords = "benchmarking, clinical practice, guideline, outcome, Standard of care, Anti-Infective Agents/therapeutic use, Cystic Fibrosis/complications, Humans, Europe, Denmark",

author = "Tavs Qvist and Nielsen, {Bibi Uhre} and Olesen, {Hanne Vebert} and Mathiesen, {Inger Hee Mabuza} and Daniel Faurholt-Jepsen and Katzenstein, {Terese L.} and Jannik Helweg-Larsen and Frederikke R{\"o}nsholt and Majbritt Jeppesen and Olsen, {Mette Frahm} and Buchvald, {Frederik Fouirnaies} and Nielsen, {Kim Gjerum} and S{\o}ren Jensen-Fangel and Tania Pressler and Marianne Skov",

note = "Publisher Copyright: {\textcopyright} 2024 The Authors. APMIS published by John Wiley & Sons Ltd on behalf of Scandinavian Societies for Pathology, Medical Microbiology and Immunology.",

year = "2024",

month = apr,

doi = "10.1111/apm.13375",

language = "English",

volume = "132",

pages = "223--235",

journal = "APMIS",

issn = "0903-4641",

publisher = "Blackwell Munksgaard",

number = "4",

}

Qvist, T, Nielsen, BU, Olesen, HV, Mathiesen, IHM, Faurholt-Jepsen, D, Katzenstein, TL, Helweg-Larsen, J, Rönsholt, F, Jeppesen, M, Olsen, MF, Buchvald, FF, Nielsen, KG, Jensen-Fangel, S, Pressler, T & Skov, M 2024, 'Close monitoring and early intervention: management principles for cystic fibrosis in Denmark', APMIS, vol. 132, no. 4, pp. 223-235. https://doi.org/10.1111/apm.13375

TY - JOUR

T1 - Close monitoring and early intervention

T2 - management principles for cystic fibrosis in Denmark

AU - Qvist, Tavs

AU - Nielsen, Bibi Uhre

AU - Olesen, Hanne Vebert

AU - Mathiesen, Inger Hee Mabuza

AU - Faurholt-Jepsen, Daniel

AU - Katzenstein, Terese L.

AU - Helweg-Larsen, Jannik

AU - Rönsholt, Frederikke

AU - Jeppesen, Majbritt

AU - Olsen, Mette Frahm

AU - Buchvald, Frederik Fouirnaies

AU - Nielsen, Kim Gjerum

AU - Jensen-Fangel, Søren

AU - Pressler, Tania

AU - Skov, Marianne

PY - 2024/4

Y1 - 2024/4

N2 - Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.

AB - Cystic fibrosis (CF) care in Denmark has been characterized by close monitoring and pre-emptive treatment of lung disease and other CF-related complications. Continuous evaluation through data collection and commitment to clinical research has incrementally improved outcomes. This approach has been in line with best practices set forth by European Standards of Care but has also gone beyond Society standards particularly pertaining to early treatment with high-dose combination antimicrobial therapy. Despite a high prevalence of severe CF variants, lung function has been among the best in Europe. In this review, the Danish approach to management of CF prior to the introduction of new CF modulator treatment is explained and benchmarked. Downsides to the Danish approach are discussed and include increased burden of treatment, risk of antimicrobial resistance, side-effects and costs.

KW - benchmarking

KW - clinical practice

KW - guideline

KW - outcome

KW - Standard of care

KW - Anti-Infective Agents/therapeutic use

KW - Cystic Fibrosis/complications

KW - Humans

KW - Europe

KW - Denmark

UR - http://www.scopus.com/inward/record.url?scp=85183001195&partnerID=8YFLogxK

U2 - 10.1111/apm.13375

DO - 10.1111/apm.13375

M3 - Review

C2 - 38267398

AN - SCOPUS:85183001195

SN - 0903-4641

VL - 132

SP - 223

EP - 235

JO - APMIS

JF - APMIS

IS - 4

ER -

Close monitoring and early intervention: management principles for cystic fibrosis in Denmark

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this